Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.

被引：0
|
作者：
Bachelot, T.
Bajard, A.
Ray-Coquard, I
Coeffic, D.
Dramais, D.
Ferri-Dessens, R.-M.
Guastalla, J.-P.
Perol, D.
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Hosp, Annecy, France
[3] Inst Daniel Hollard, Grenoble, France
[4] Ctr Hosp, Valence, France
[5] Roche France, Paris, France
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：625S / 625S
页数：1
相关论文
共 50 条
  • [31] Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
    Serafín Morales
    Antonio Lorenzo
    Manuel Ramos
    Pedro Ballesteros
    Miguel Méndez
    Concepción Almanza
    Javier Castellanos
    José Andrés Moreno-Nogueira
    Joaquín Casal
    José Lizón
    Amparo Oltra
    Adolfo Frau
    Ignacio Machengs
    Antonio Galán
    Joaquín Belón
    Cristina Llorca
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 75 - 81
  • [32] Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer:: results of a large, multicentre phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Castellanos, J
    Moreno-Nogueira, JA
    Casal, J
    Lizón, J
    Oltra, A
    Frau, A
    Machengs, I
    Galán, A
    Belón, J
    Llorca, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (01) : 75 - 81
  • [33] Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
    Serafín Morales
    Antonio Lorenzo
    Manuel Ramos
    Pedro Ballesteros
    Miguel Méndez
    Concepción Almanza
    Javier Castellanos
    José Andrés Moreno-Nogueira
    Joaquín Casal
    José Lizón
    Amparo Oltra
    Adolfo Frau
    Ignacio Machengs
    Antonio Galán
    Joaquín Belón
    Cristina Llorca
    Cancer Chemotherapy and Pharmacology, 2004, 53 (1) : 75 - 81
  • [34] Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer
    Amarantidis, K.
    Xenidis, N.
    Chelis, L.
    Chamalidou, E.
    Dimopoulos, P.
    Michailidis, P.
    Tentes, A.
    Deftereos, S.
    Karanikas, M.
    Karayiannakis, A.
    Kakolyris, S.
    ONCOLOGY, 2011, 80 (5-6) : 359 - 365
  • [35] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [36] Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
    Martin, Miguel
    Ruiz Simon, Amparo
    Ruiz Borrego, Manuel
    Ribelles, Nuria
    Rodriguez-Lescure, Alvaro
    Munoz-Mateu, Montserrat
    Gonzalez, Sonia
    Margeli Vila, Mireia
    Barnadas, Agusti
    Ramos, Manuel
    Del Barco Berron, Sonia
    Jara, Carlos
    Calvo, Lourdes
    Martinez-Janez, Noelia
    Mendiola Fernandez, Cesar
    Rodriguez, Cesar A.
    Martinez de Duenas, Eduardo
    Andres, Raquel
    Plazaola, Arrate
    de la Haba-Rodriguez, Juan
    Manuel Lopez-Vega, Jose
    Adrover, Encarna
    Isabel Ballesteros, Ana
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    Baena-Canada, Jose M.
    Casas, Maribel
    del Carmen Camara, Mara
    Maria Carrasco, Eva
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3788 - +
  • [37] Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer -: Final results of a dose-finding and efficacy study
    Viens, P
    Roché, H
    Kerbrat, P
    Fumoleau, P
    Guastalla, JP
    Delozier, T
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (04): : 328 - 335
  • [38] Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Miles, David W.
    Chan, Arlene
    Dirix, Luc Y.
    Cortes, Javier
    Pivot, Xavier
    Tomczak, Piotr
    Delozier, Thierry
    Sohn, Joo Hyuk
    Provencher, Louise
    Puglisi, Fabio
    Harbeck, Nadia
    Steger, Guenther G.
    Schneeweiss, Andreas
    Wardley, Andrew M.
    Chlistalla, Andreas
    Romieu, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3239 - 3247
  • [39] Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)
    Mansutti, M.
    Cavazzini, G.
    Lorusso, V.
    Boni, C.
    Occelli, M.
    Puglisi, F.
    Del Mastro, L.
    Venturini, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Final results of the AGO breast cancer study group MAMMA-3 trial:: first-line capecitabine plus paclitaxel vs epirubicin plus paclitaxel for high-risk metastatic breast cancer
    Lueck, H-J
    du Bois, A.
    Schrade, I
    Huober, J.
    Heilmann, V
    Fasching, P. A.
    Staehle, A.
    Jackisch, C.
    Marth, C.
    Richter, B.
    von Minckwitz, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S67 - S67
12345